Strategic Partnerships KCAS Bio - Philadelphia partners with Alamar Biosciences as a CSP for the Argo HT platform, enabling NULISA services. This creates cross-sell opportunities for clients using Alamar technologies and positions KCAS as a preferred CRO for advanced cytometry workflows.

Global Conference Footprint Active participation in major cytometry and biotech events (CYTO, AIS, Swiss Biotech Day, ASMS, NextGen Biomed) through 2026 provides multiple touchpoints to engage prospective pharma and biotech clients seeking specialized flow cytometry services and preclinical to clinical development support.

Expanded Service Portfolio Services span from preclinical to clinical development with polychromatic flow cytometry, cell sorting, and aseptic processing. This breadth can attract larger pharma accounts seeking end-to-end cytometry capabilities, offering upsell opportunities for broader project scopes.

Adoption of Advanced Tech Certified Service Provider status for the Argo HT platform and NULISA capabilities signal cutting-edge capabilities. Marketing these differentiators can attract clients prioritizing high-throughput, high-plex cytometry and rapid timelines.

Diverse Client Network A diversified client base across pharmaceutical, biotech, and academic institutions combined with a mid-market revenue profile ($1M–$10M) suggests opportunities to target mid-size biotechs expanding their preclinical-to-clinical programs and seeking cost-competitive CRO partnerships.